FrancophonIA/ELRC3.0 huggingface dataset:
English: At 600 microgram once-daily, the safety profile of Oslif Breezhaler was overall similar to that of recommended doses.
Estonian: 600 mikrogrammi üks kord päevas annuse korral oli Oslif Breezhaler'i ohutusprofiil üldiselt sarnane soovitatud annuste puhul täheldatuga.
English: Like other beta2-adrenergic agonists, indacaterol may produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, blood pressure, and/or symptoms.
Estonian: Sarnaselt teiste beeta-2-adrenomimeetikumidega võib indakaterool mõnedel patsientidel esile kutsuda kliiniliselt olulise kardiovaskulaarse toime, mis avaldub pulsisageduse kiirenemise, vererõhu tõusu ja/või sümptomite sagenemisena.
English: Oslif Breezhaler was shown to reduce lung hyperinflation, resulting in increased inspiratory capacity during exercise and at rest, compared to placebo.
Estonian: Oslif Breezhaler vähendas kopsude hüperinflatsiooni, mille tulemusena suurenes inspiratoorne kapatsiteet vastavalt koormusel ja puhkeolekus võrreldes platseeboga.
English: It is not harmful if these pieces are swallowed or inhaled.
Estonian: Nende tükikeste neelamine või sissehingamine ei ole ohtlik.
English: Inhalation of high doses of beta2-adrenergic agonists may produce increases in plasma glucose.
Estonian: Beeta-2-adrenomimeetikumide suurte annuste inhaleerimise järgselt võib tekkida plasma glükoosisisalduse suurenemine.
English: In COPD patients, single doses of 10 times the maximum recommended therapeutic dose were associated with a moderate increase in pulse rate, systolic blood pressure and QTc interval.
Estonian: KOKihaigetel seostati maksimaalsest soovitatavast terapeutilisest annusest 10 korda suuremaid ühekordseid annuseid pulsisageduse mõõduka kiirenemise, süstoolse vererõhu mõõduka tõusu ja QTc-intervalli mõõduka pikenemisega.
English: Therefore, this shows no concern for a pro-arrhythmic potential related to QT-interval prolongations at recommended therapeutic doses or at twice the maximum recommended dose.
Estonian: Seetõttu puudub QT-intervalli pikenemisega seotud proarütmilise toime risk soovitatud terapeutiliste annuste või maksimaalsest soovitatavast annusest kaks korda suuremate annuste manustamisel.
English: Therefore, long-acting beta2-adrenergic agonists such as Oslif Breezhaler should be used with caution in patients with known or suspected prolongation of the QT interval or treated with medicinal products affecting the QT interval.
Estonian: Seega tuleb pikatoimelisi beeta-2-adrenomimeetikume kasutada ettevaatusega patsientidel, kellel esineb või kahtlustatakse QT-intervalli pikenemist või kes kasutavad QT-intervalli mõjutavaid ravimpreparaate.
English: Sympathomimetic medicinal products
Estonian: Sümpatomimeetilise toimega ravimid
English: 1.0 b a n/e a
Estonian: 1,2 a n/e
English: Insert capsule: Place the capsule into the capsule chamber.
Estonian: Paigaldage kapsel: Asetage kapsel kapsli pessa.
English: • if you get crushing chest pain, (common).
Estonian: • kui teil tekib pigistav valu rinnus (sage).
English: Novartis Bulgaria EOOD Тел.
Estonian: Novartis Bulgaria EOOD
English: The other ingredients include lactose and the capsule is made of gelatin.
Estonian: Teised koostisosad on laktoos ja želatiin, mis on kapsli koostises.
English: COPD is a long-term disease and you should use Oslif Breezhaler every day and not only when you have breathing problems or other symptoms of COPD.
Estonian: − KOK on pikaajaline haigus ja te peate kasutama Oslif Breezhaler'it iga päev ja mitte ainult siis,
English: • pain in muscles, bones or joints
Estonian: • lihaste, luude või liigeste valu
English: On the inside of the pack there is a daily dose tracker.
Estonian: Pakendi siseküljel on ööpäevase annuse meelespea.
English: Tiotropium once a day
Estonian: Tiotroopium 1x päevas
English: In the event of deterioration of COPD during treatment with Oslif Breezhaler, a re-evaluation of the patient and of the COPD treatment regimen should be undertaken.
Estonian: Kui ravi ajal Oslif Breezhaler'iga tekib KOKi süvenemine, tuleb patsiendi seisundit ja KOKi raviskeemi uuesti hinnata.
English: The capsules must be administered only using the Oslif Breezhaler inhaler (see section 6.6).
Estonian: Kapslite manustamiseks tohib kasutada ainult Oslif Breezhaler inhalaatorit (vt lõik 6.6).
English: At the recommended doses, the adverse reaction profile of Oslif Breezhaler in patients with COPD shows clinically insignificant systemic effects of beta2-adrenergic stimulation.
Estonian: Soovitatud annuste puhul näitab Oslif Breezhaler'i kõrvaltoimete profiil KOKihaigetel kliiniliselt ebaolulisi süsteemseid toimeid seoses beeta-2-adrenergilise stimulatsiooniga.
English: This opens the inhaler.
Estonian: Nii saab inhalaatori avada.
English: Hold the base of the inhaler firmly and tilt the mouthpiece.
Estonian: Hoidke kindlalt kinni inhalaatori põhjast ja kallutage huulikut.
English: Your doctor may tell you to use the 150 microgram capsule or the 300 microgram capsule depending on your condition and on how you respond to the treatment.
Estonian: Arst võib sõltuvalt teie seisundist ja ravivastusest öelda, et kasutaksite 150-mikrogrammist kapslit või 300-mikrogrammist kapslit.
English: Do not take the inhaler apart.
Estonian: − Ärge võtke inhalaatorit osadeks lahti.
English: Renal impairment No dose adjustment is required for patients with renal impairment.
Estonian: Neerukahjustusega patsientidel ei ole vaja annust muuta.
English: Nevertheless, it is considered unlikely that indacaterol will affect reproductive or fertility performance in humans following inhalation of the maximum recommended dose (see section 5.3).
Estonian: Sellegipoolest on ebatõenäoline, et maksimaalse soovitatava annuse inhaleerimise järgselt mõjutab indakaterool inimestel reproduktiivsust ja viljakust (vt lõik 5.3).
English: Oslif Breezhaler contains lactose
Estonian: Oslif Breezhaler sisaldab laktoosi
English: Indacaterol serum concentrations increased with repeated once-daily administration.
Estonian: Indakaterooli kontsentratsioon seerumis suurenes korduval üks kord päevas manustamisel.
English: A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Oslif Breezhaler therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Estonian: Rinnaga toitmise katkestamine või ravi katkestamine/jätkamine, tuleb otsustada arvestades imetamise kasu lapsele ja ravi kasu naisele.
English: The Oslif Breezhaler Phase III clinical development programme involved patients with a clinical diagnosis of moderate to severe COPD.
Estonian: Oslif Breezhaler'i III faasi kliinilises arendusprogrammis osalesid patsiendid, kelle kliiniliseks diagnoosiks oli keskmise raskusega või raske KOK.
English: Both doses resulted in an increase of 40-50 ml over open-label tiotropium 18 microgram once a day (150 microgram, p=0.004; 300 microgram, p=0.01).
Estonian: Mõlemad annused viisid FEV1 40...50 ml suurenemiseni võrreldes üks kord päevas manustatud 18 mikrogrammi avatud sildiga tiotroopiumiga (150 mikrogrammi, p=0,004; 300 mikrogrammi, p=0,01).
English: Indacaterol once a day
Estonian: Indakaterool 1x päevas
English: Mass balance was complete with ≥90% of the dose recovered in the excreta.
Estonian: ≥90% annusest avastati väljaheidetes.
English: The Oslif Breezhaler inhaler provided with each new prescription should be used.
Estonian: Kasutada tuleb iga uue retseptiga ette nähtud Oslif Breezhaler inhalaatorit.
English: When you inhale it, it relaxes the muscles in the walls of the small air passages in the lungs.
Estonian: Ravimi sissehingamisel lõõgastuvad lihased väikeste hingamisteede seintes.
English: INNER LID OF OUTER CARTON OF UNIT PACK AND OF INTERMEDIATE CARTON OF MULTIPACK
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED ÜKSIKPAKENDI KARBI JA MULTIPAKENDI VAHEPAKENDI SISEKÜLG
English: Metabolism and nutrition disorders Diabetes mellitus and hyperglycaemia
Estonian: Ainevahetus-ja toitumishäired Diabeet ja hüperglükeemia
English: Mean peak improvements in FEV1 relative to baseline were 250-330 ml at steady state.
Estonian: FEV1 keskmine maksimaalne paranemine algväärtusest oli 250...330 ml püsikontsentratsiooni faasis.
English: The recommended dose is the inhalation of the content of one 150 microgram capsule once a day, using the Oslif Breezhaler inhaler.
Estonian: Soovitatavaks annuseks on ühe 150-mikrogrammise kapsli sisu inhalatsioon üks kord päevas Oslif Breezhaler inhalaatorist.
English: Immediate hypersensitivity reactions have been reported after administration of Oslif Breezhaler.
Estonian: On teatatud kohestest ülitundlikkusreaktsioonidest pärast Oslif Breezhaler'i manustamist.
English: Paediatric population There is no relevant use of Oslif Breezhaler in the paediatric population (under 18 years).
Estonian: Puudub Oslif Breezhaler'i asjakohane kasutus lastel (vanuses alla 18 aasta).
English: Deutschland Novartis Pharma GmbH Tel: +49 911 273 0
Estonian: De uts chland Novartis Pharma GmbH Tel: +49 911 273 0
English: Do not swallow.
Estonian: Mitte neelata.
English: How to clean your inhaler
Estonian: Kuidas inhalaatorit puhastada
English: Beta2-adrenergic agonists may produce significant hypokalaemia in some patients, which has the potential to produce adverse cardiovascular effects.
Estonian: Beeta-2-adrenomimeetikumid võivad mõnedel patsientidel esile kutsuda väljendunud hüpokaleemia, mis võib põhjustada kardiovaskulaarseid kõrvaltoimeid.
English: The capsules must only be removed from the blister immediately before use.
Estonian: Kapsleid tuleb blistrist eemaldada alles vahetult enne kasutamist.
English: The mean accumulation ratio of indacaterol, i.e. AUC over the 24-h dosing interval on Day 14 compared to Day 1, was in the range of 2.9 to 3.5 for once-daily inhaled doses between 150 microgram and 600 microgram.
Estonian: Indakaterooli keskmine akumulatsiooni suhe, st AUC 24-tunnise manustamisintervalli jooksul jäi 14. päeval võrreldes 1. päevaga vahemikku 2,9...3,5 150...600-mikrogrammiste inhaleeritavate annuste manustamisel üks kord päevas.
English: Open inhaler:
Estonian: Avage inhalaator:
English: An increase in the daily dose of Oslif Breezhaler beyond the maximum dose of 300 microgram is not appropriate.
Estonian: Oslif Breezhaler'i ööpäevast annust ei tohi suurendada üle maksimaalse annuse, milleks on 300 mikrogrammi.
English: Do not blow into the mouthpiece.
Estonian: Ärge puhuge huulikusse.
English: • if you get symptoms of an allergic reaction such as rash, itching, hives, difficulty breathing or swallowing, dizziness (uncommon).
Estonian: • kui teil tekivad allergilise reaktsiooni nähud, näiteks lööve, sügelus, nõgestõbi, hingamis- või neelamisraskused, pearinglus (aeg-ajalt).
English: Clinically relevant effects on prolongation of the QTc-interval have not been observed in clinical studies of Oslif Breezhaler at recommended therapeutic doses (see section 5.1).
Estonian: Oslif Breezhaler'i kliinilistes uuringutes ei ole soovitatavate terapeutiliste annuste kasutamisel täheldatud kliiniliselt olulisi toimeid QTc-intervalli pikenemisele (vt lõik 5.1).
English: Oslif Breezhaler, administered once a day at doses of 150 microgram and 300 microgram, showed clinically meaningful improvements in lung function.
Estonian: Oslif Breezhaler'i manustamine üks kord päevas annustes 150 ja 300 mikrogrammi viis kopsufunktsiooni kliiniliselt olulise paranemiseni.
English: There are no data available for use of Oslif Breezhaler in patients with severe hepatic impairment.
Estonian: Puuduvad andmed Oslif Breezhaler'i kasutamise kohta raske maksakahjustusega patsientidel.
English: Oslif Breezhaler contains the active substance indacaterol which belongs to a group of medicines called bronchodilators.
Estonian: Oslif Breezhaler sisaldab toimeainena indakaterooli, mis kuulub bronhodilataatoriteks ehk bronhilõõgastiteks nimetatud ravimite rühma.
English: During clinical studies, clinically notable changes in blood glucose were generally more frequent by 1-2% on Oslif Breezhaler at the recommended doses than on placebo.
Estonian: Kliinilistes uuringutes esines Oslif Breezhaler'i soovitatavate annuste kasutamisel veresuhkru taseme kliiniliselt väljendunud muutusi üldiselt sagedamini (1...2% võrra) kui platseebo puhul.
English: 46 b 40 c
Estonian: 38 a 46 b 40 c
English: Like other beta2-adrenergic agonists, indacaterol may inhibit labour due to a relaxant effect on uterine smooth muscle.
Estonian: Sarnaselt teiste beeta-2-adrenomimeetikumidega võib indakaterool pärssida sünnitustegevust emaka silelihaseid lõõgastava toime tõttu.
English: • Open the mouthpiece again, and remove the empty capsule by tipping it out of the capsule chamber.
Estonian: • Avage uuesti huulik ja eemaldage tühi kapsel pesast.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE/MÜÜGILOA UUENDAMISE KUUPÄEV Müügiloa esmase väljastamise kuupäev: 30. november 2009
English: Oslif Breezhaler capsules must not be swallowed.
Estonian: Oslif Breezhaler kapsleid ei tohi alla neelata.
English: OUTER CARTON OF MULTIPACK (INCLUDING BLUE BOX)
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED MULTIPAKENDI VÄLISPAKEND (SH BLUE BOX)
English: If you forget to use Oslif Breezhaler
Estonian: Kui te unustate Oslif Breezhaler'it kasutada
English: Always keep the Oslif Breezhaler inhaler and capsules in a dry place.
Estonian: − Hoidke Oslif Breezhaler inhalaatorit ja kapsleid alati kuivas kohas.
English: Oslif Breezhaler is not indicated for the treatment of acute episodes of bronchospasm, i.e. as rescue therapy.
Estonian: Oslif Breezhaler ei ole näidustatud ägedate bronhospasmi episoodide raviks, st hooravimina.
English: Indacaterol is a partial agonist at the human beta2-adrenergic receptor with nanomolar potency.
Estonian: Indakaterool on nanomolaarse aktiivsusega partsiaalne agonist inimese beeta2-adrenoretseptorite tasemel.
English: if you have diabetes.
Estonian: − kui teil on suhkurtõbi.
English: Due to the very low contribution of the urinary pathway to total body elimination, a study in renally impaired subjects was not performed.
Estonian: Kuna neerudel on ravimi eliminatsioonis väga väike roll, siis neerukahjustusega patsientidel uuringut läbi ei viidud.
English: • cold-like symptoms.
Estonian: • külmetuselaadsed nähud.
English: Do not use Oslif Breezhaler capsules with any other inhaler, and do not use Oslif Breezhaler inhaler to take any other capsule medicine.
Estonian: Oslif Breezhaler kapsleid üheski teises inhalaatoris, samuti ärge kasutage Oslif Breezhaler inhalaatorit ühegi teise kapslites ravimi manustamiseks.
English: What you need to know before you use Oslif Breezhaler
Estonian: Mida on vaja teada enne Oslif Breezhaler'i kasutamist
English: The oxidative metabolites were found in incubations with recombinant CYP1A1, CYP2D6, and CYP3A4.
Estonian: Oksüdatiivsed metaboliidid leiti inkubeerimisel rekombinantse CYP1A1, CYP2D6 ja CYP3A4-ga. CYP3A4 loetakse põhiliseks isoensüümiks, mis vastutab indakaterooli hüdroksüülimise eest.
English: Oslif Breezhaler 150 microgram capsules have a black product code “IDL 150” printed above a black bar and a black company logo ( ) printed below the black bar.
Estonian: − Oslif Breezhaler 150-mikrogrammistele kapslitele on trükitud mustas kirjas toote kood „IDL 150“ musta joone kohale ja firma logo ( ) musta joone alla.
English: Inhale the medicine: To breathe the medicine deeply into your airways:
Estonian: Ravimi sissehingamine: Et ravim jõuaks sissehingamisel sügavale hingamisteedesse:
English: The 300 microgram dose resulted in a 170-180 ml increase compared to placebo (p<0.001) and a 100 ml increase compared to formoterol 12 microgram twice a day (p<0.001).
Estonian: 300-mikrogrammine annus viis FEV1 170...180 ml suurenemiseni võrreldes platseeboga (p<0,001) ja 100 ml suurenemiseni võrreldes kaks korda päevas manustatud 12 mikrogrammi formoterooliga (p<0,001).
English: • Only use the Oslif Breezhaler inhaler contained in this pack.
Estonian: • Kasutage ainult selles pakendis sisalduvat Oslif Breezhaler inhalaatorit.
English: The pharmacological effects of beta2-adrenoceptor agonists are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyses the conversion of adenosine triphosphate (ATP) to cyclic-3', 5'-adenosine monophosphate (cyclic monophosphate).
Estonian: See on ensüüm, mis katalüüsib adenosiintrifosfaadi (ATP) konversiooni tsükliliseks 3',5'-adenosiinmonofosfaadiks (tsükliline monofosfaat).
English: Oslif Breezhaler 300 microgram capsules have a blue product code “IDL 300” printed above a blue bar and a blue company logo ( ) printed below the blue bar.
Estonian: − Oslif Breezhaler 300-mikrogrammistele kapslitele on trükitud sinises kirjas toote kood „IDL 300“ sinise joone kohale ja firma logo ( ) sinise joone alla.
English: Oslif Breezhaler inhaler
Estonian: Oslif Breezhaler inhalaator
English: Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Estonian: Muud ravimid ja Oslif Breezhaler Teatage oma arstile või apteekrile, kui te võtate või olete hiljuti võtnud või kavatsete võtta mis tahes muid ravimeid.
English: The powder in the capsules is for you to inhale.
Estonian: Kapslites sisalduv pulber on sisse hingamiseks.
English: No dose adjustment is required for patients with mild and moderate hepatic impairment.
Estonian: Kerge ja mõõduka maksakahjustusega patsientidel ei ole vaja annust muuta.
English: Novartis Europharm Limited
Estonian: MÜÜGILOA HOIDJA NIMI Novartis Europharm Limited
English: Only use the capsules with the inhaler provided in this pack (Oslif Breezhaler inhaler).
Estonian: − Kasutage kapsleid ainult koos selles pakendis oleva inhalaatoriga (Oslif Breezhaler inhalaator).
English: Stop using the medicine and tell your doctor immediately if you get tightness of the chest, coughing, wheezing or breathlessness immediately after using the medicine.
Estonian: − Kui teil tekib vahetult pärast ravimi kasutamist rindkere pingsus, köha, vilisev hingamine või hingeldus, lõpetage otsekohe ravimi kasutamine ja teavitage sellest oma arsti.
English: 47 b 41 c
Estonian: 45 a 47 b 41 c
English: Symptomatic benefits
Estonian: Sümptomaatiline toime
English: In COPD the muscles around the airways tighten.
Estonian: KOKi korral on lihased hingamisteede ümber pinguldunud.
English: Do not press the side buttons.
Estonian: Ärge vajutage küljenuppe.
English: Cough is a common symptom in COPD.
Estonian: Köha on sage sümptom KOKi puhul.
English: Do not use more than your doctor tells you to use.
Estonian: Ärge kasutage arsti poolt määratust rohkem ravimit.
English: At the 12-week primary endpoint (24-hour trough FEV1), the 150 microgram dose resulted in a 130-180 ml increase compared to placebo (p<0.001) and a 60 ml increase compared to salmeterol 50 microgram twice a day (p<0.001).
Estonian: 12 nädala esmase tulemusnäitaja (24. tunni minimaalse FEV1) osas viis 150-mikrogrammine annus FEV1 130...180 ml suurenemiseni võrreldes platseeboga (p<0,001) ja 60 ml suurenemiseni võrreldes kaks korda päevas manustatud 50 mikrogrammi salmeterooliga (p<0,001).
English: • swollen hands, ankles and feet (oedema)
Estonian: • käte, pahkluude piirkonna ja labajalgade turse
English: Inhaler body and cap are made from acrylonitrile butadiene styrene, push buttons are made from methyl methacrylate acrylonitrile butadiene styrene.
Estonian: Inhalaatori korpus ja kork on valmistatud akrülonitriilbutadieenstüreenist, nupud on valmistatud metüülmetakrülaatakrülonitriilbutadieenstüreenist.
English: - Each Oslif Breezhaler 300 microgram capsule contains 300 microgram indacaterol as indacaterol maleate.
Estonian: Iga Oslif Breezhaler 300-mikrogrammine kapsel sisaldab 300 mikrogrammi indakaterooli indakateroolmaleaadina.
English: 54 c a
Estonian: 54 a
English: Treatment comparison compared to placebo showed a ratio of rates of 0.68 (95% CI [ 0.47, 0.98]; p-value 0.036) and 0.74 (95% CI [0.56, 0.96]; pvalue 0.026) for 150 microgram and 300 microgram, respectively.
Estonian: 0,036) ja 0,74 (95% CI [0,56, 0,96]; p-väärtus 0,026) vastavalt 150 mikrogrammi ja 300 mikrogrammi puhul.
English: • You should hear a “click” as the capsule is being pierced.
Estonian: • Kapsli läbistamisel kostub „plõksatus“.
English: Oslif Breezhaler is a single-dose inhalation device.
Estonian: Oslif Breezhaler on inhalatsiooniseade ühekordse annuse manustamiseks.
English: c: indacaterol 300 microgram, formoterol and placebo MCID = minimal clinically important difference (≥1 point change in TDI, ≥4 point change in SGRQ) n/e= not evaluated at six months
Estonian: Uuringu ülesehitus a: indakaterool 150 mikrogrammi, salmeterool ja platseebo; b: indakaterool 150 ja 300 mikrogrammi, tiotroopium ja platseebo; c: indakaterool 300 mikrogrammi, formoterool ja platseebo † MCID = minimaalne kliiniliselt oluline erinevus (≥1 punkti muutus - TDI, ≥4 punkti muutus - SGRQ) n/e= ei hinnatud kuuendal kuul
English: In a human ADME study where indacaterol was given orally, the faecal route of excretion was dominant over the urinary route.
Estonian: Inimeste ADME uuringus, kus indakaterooli manustati suu kaudu, eritus ravimit rohkem rooja kui uriiniga.
English: 51 c a
Estonian: 51 c
English: Carton containing 30 capsules and one Oslif Breezhaler inhaler.
Estonian: Karbis on 30 kapslit ja üks Oslif Breezhaler inhalaator.
English: Transparent (uncoloured) capsules containing a white powder, with “IDL 300” printed in blue above a blue bar and company logo ( ) printed in blue below the blue bar.
Estonian: Valget pulbrit sisaldavad läbipaistvad (värvitud) kapslid, millele on sinises kirjas trükitud „IDL 300“ sinise joone kohale ja firma logo ( ) sinise joone alla.
English: Show the pack of Oslif Breezhaler.
Estonian: Näidake Oslif Breezhaler'i pakendit.
English: Only use the Oslif Breezhaler inhaler contained in this pack.
Estonian: − Kasutage ainult selles pakendis sisalduvat Oslif Breezhaler inhalaatorit.
English: • Do not swallow the capsules.
Estonian: • Ärge kapsleid alla neelake.
English: Oslif Breezhaler is used to make breathing easier for adult patients who have breathing difficulties due to a lung disease called chronic obstructive pulmonary disease (COPD).
Estonian: Oslif Breezhaler'it kasutatakse hingamise kergemaks muutmiseks kroonilisest obstruktiivsest kopsuhaigusest (KOK) tingitud hingamisraskustega täiskasvanutel.
English: 30 capsules and 1 inhaler.
Estonian: 30 kapslit ja 1 inhalaator.
English: The Oslif Breezhaler inhaler enables you to inhale the medicine contained in a capsule.
Estonian: Oslif Breezhaler inhalaator võimaldab kapslis sisalduvat ravimit sisse hingata.
English: Oslif Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD).
Estonian: Oslif Breezhaler on näidustatud bronhe lõõgastavaks säilitusraviks hingamisteede obstruktsiooni korral kroonilise obstruktiivse kopsuhaigusega (KOK) täiskasvanud patsientidel.
English: Carton containing 10 capsules and one Oslif Breezhaler inhaler.
Estonian: Karbis on 10 kapslit ja üks Oslif Breezhaler inhalaator.
English: You should not use Oslif Breezhaler unless your doctor tells you so.
Estonian: Oslif Breezhaler'it tohib kasutada ainult juhul, kui arst seda soovitab.
English: Never wash the Oslif Breezhaler inhaler with water.
Estonian: − Ärge kunagi peske Oslif Breezhaler inhalaatorit veega.
English: The Oslif Breezhaler inhaler enables you to inhale the medicine contained in an Oslif Breezhaler capsule.
Estonian: Oslif Breezhaler inhalaator võimaldab sisse hingata Oslif Breezhaler kapslis sisalduvat ravimit.
English: Musculoskeletal and connective tissue disorders Muscle spasm
Estonian: Lihas-skeleti ja sidekoe kahjustused Lihasspasm
English: Tell your doctor immediately if your COPD symptoms (breathlessness, wheezing, cough) do not improve or get worse.
Estonian: − Kui KOKi sümptomid (hingeldus, vilisev hingamine, köha) ei parane või süvenevad, rääkige sellest otsekohe oma arstile.
English: Luxembourg/Luxemburg Novartis Pharma N.V.
Estonian: Luxe mbourg/Luxe mburg Novartis Pharma N.V.